Axovant Sciences (AXON -0.9%) announces that the FDA is on board with the inclusion of data on its first-generation version of gene therapy AXO-Lenti-PD, called ProSavin, to support the development plan of the second-generation version for the treatment of Parkinson's disease (PD).
A Phase 2 clinical trial, SUNRISE-PD, was initiated in the UK on October. The primary endpoint is safety. Secondary endpoints include efficacy measures. According to ClinicalTrials.gov, the estimated primary completion date is June 2022, although the company plans to release data on the first two patients in March 2019.
Now read: Moderna IPO: Very Expensive »
Subscribe for full text news in your inbox